This company listing is no longer active
Idogen (IDOGEN) Stock Overview
Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs, and the body’s own cells or tissues in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
IDOGEN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Idogen AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.12 |
| 52 Week High | SEK 0.55 |
| 52 Week Low | SEK 0.015 |
| Beta | 1.78 |
| 1 Month Change | -20.20% |
| 3 Month Change | 41.76% |
| 1 Year Change | -62.92% |
| 3 Year Change | -98.22% |
| 5 Year Change | -99.58% |
| Change since IPO | -99.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| IDOGEN | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -5.5% | -0.2% | -1.2% |
| 1Y | -62.9% | -2.6% | 4.8% |
Return vs Industry: IDOGEN underperformed the Swedish Biotechs industry which returned -6.6% over the past year.
Return vs Market: IDOGEN underperformed the Swedish Market which returned 4.4% over the past year.
Price Volatility
| IDOGEN volatility | |
|---|---|
| IDOGEN Average Weekly Movement | 194.5% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 11.5% |
| 10% least volatile stocks in SE Market | 2.9% |
Stable Share Price: IDOGEN's share price has been volatile over the past 3 months.
Volatility Over Time: IDOGEN's weekly volatility has increased from 95% to 194% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 6 | Christina Herder | www.idogen.com |
Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs, and the body’s own cells or tissues in Sweden. The company’s advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection primarily kidney transplantation; and IDO AID for the treatment of autoimmune diseases.
Idogen AB (publ) Fundamentals Summary
| IDOGEN fundamental statistics | |
|---|---|
| Market cap | SEK 12.58m |
| Earnings (TTM) | -SEK 44.05m |
| Revenue (TTM) | SEK 771.00k |
Is IDOGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDOGEN income statement (TTM) | |
|---|---|
| Revenue | SEK 771.00k |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 771.00k |
| Other Expenses | SEK 44.82m |
| Earnings | -SEK 44.05m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 23, 2023
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,712.97% |
| Debt/Equity Ratio | 0% |
How did IDOGEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/11 12:00 |
| End of Day Share Price | 2023/07/06 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Idogen AB (publ) is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Klas Pyk | Nordea Markets |
| Filip Einarsson | Redeye |